Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant QL1706 plus Lenvatinib for HCC
NCT06884982Phase 2Not yet recruiting
- Sponsor
- Subei People's Hospital
- Start
- Mar 2025
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of QL1706 in hepatocellular carcinoma (HCC), sponsored by Subei People's Hospital. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06884982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06884982.